0 01/04/2023 31/03/2024 2024-03-31 false false false false false false false true false false true false false false false false false false No description of principal activities is disclosed 2023-04-01 Sage Accounts Production 23.0 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP SC576993 2023-04-01 2024-03-31 SC576993 2024-03-31 SC576993 2023-03-31 SC576993 2022-04-01 2023-03-31 SC576993 2023-03-31 SC576993 2022-03-31 SC576993 core:PlantMachinery 2023-04-01 2024-03-31 SC576993 core:FurnitureFittingsToolsEquipment 2023-04-01 2024-03-31 SC576993 core:MotorVehicles 2023-04-01 2024-03-31 SC576993 bus:Director1 2023-04-01 2024-03-31 SC576993 bus:Director2 2023-04-01 2024-03-31 SC576993 core:PlantMachinery 2023-03-31 SC576993 core:FurnitureFittingsToolsEquipment 2023-03-31 SC576993 core:MotorVehicles 2023-03-31 SC576993 core:PlantMachinery 2024-03-31 SC576993 core:FurnitureFittingsToolsEquipment 2024-03-31 SC576993 core:MotorVehicles 2024-03-31 SC576993 core:WithinOneYear 2024-03-31 SC576993 core:WithinOneYear 2023-03-31 SC576993 core:ShareCapital 2024-03-31 SC576993 core:ShareCapital 2023-03-31 SC576993 core:RetainedEarningsAccumulatedLosses 2024-03-31 SC576993 core:RetainedEarningsAccumulatedLosses 2023-03-31 SC576993 core:BetweenOneFiveYears 2023-03-31 SC576993 core:CostValuation core:Non-currentFinancialInstruments 2023-03-31 SC576993 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-03-31 SC576993 core:DisposalsRepaymentsInvestments core:Non-currentFinancialInstruments 2024-03-31 SC576993 core:CostValuation core:Non-currentFinancialInstruments 2024-03-31 SC576993 core:Non-currentFinancialInstruments 2024-03-31 SC576993 core:Non-currentFinancialInstruments 2023-03-31 SC576993 core:PlantMachinery 2023-03-31 SC576993 core:FurnitureFittingsToolsEquipment 2023-03-31 SC576993 core:MotorVehicles 2023-03-31 SC576993 bus:Director1 2023-03-31 SC576993 bus:Director1 2024-03-31 SC576993 bus:Director2 2023-03-31 SC576993 bus:Director2 2024-03-31 SC576993 bus:Director1 2022-03-31 SC576993 bus:Director1 2023-03-31 SC576993 bus:Director2 2022-03-31 SC576993 bus:Director2 2023-03-31 SC576993 bus:Director1 2022-04-01 2023-03-31 SC576993 bus:Director2 2022-04-01 2023-03-31 SC576993 bus:SmallEntities 2023-04-01 2024-03-31 SC576993 bus:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 SC576993 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 SC576993 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 SC576993 bus:FullAccounts 2023-04-01 2024-03-31
Company registration number: SC576993
SNMHF Medical Limited
Unaudited filleted financial statements
31 March 2024
SNMHF Medical Limited
Contents
Statement of financial position
Notes to the financial statements
SNMHF Medical Limited
Statement of financial position
31 March 2024
2024 2023
Note £ £ £ £
Fixed assets
Tangible assets 5 2,416 3,223
Investments 6 4,289 7,953
_______ _______
6,705 11,176
Current assets
Debtors 7 18,242 19,970
Cash at bank and in hand 5,272 5,320
_______ _______
23,514 25,290
Creditors: amounts falling due
within one year 8 ( 23,485) ( 26,672)
_______ _______
Net current assets/(liabilities) 29 ( 1,382)
_______ _______
Total assets less current liabilities 6,734 9,794
_______ _______
Net assets 6,734 9,794
_______ _______
Capital and reserves
Called up share capital 10 10
Profit and loss account 6,724 9,784
_______ _______
Shareholders funds 6,734 9,794
_______ _______
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 03 March 2025 , and are signed on behalf of the board by:
Dr Natalia Ferri Dr Steven Hamilton
Director Director
Company registration number: SC576993
SNMHF Medical Limited
Notes to the financial statements
Year ended 31 March 2024
1. General information
The company is a private company limited by shares, registered in Scotland. The address of the registered office is Westfields, Maryculter, Aberdeen, AB12 5GX.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Turnover
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Operating leases
Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.
Tangible assets
tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Plant and machinery - 25 % reducing balance
Fittings fixtures and equipment - 25 % reducing balance
Motor vehicles - 25 % reducing balance
If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
Fixed asset investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses. Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Employee numbers
The average number of persons employed by the company during the year amounted to Nil (2023: Nil).
5. Tangible assets
Plant and machinery Fixtures, fittings and equipment Motor vehicles Total
£ £ £ £
Cost
At 1 April 2023 and 31 March 2024 364 401 16,300 17,065
_______ _______ _______ _______
Depreciation
At 1 April 2023 309 290 13,244 13,843
Charge for the year 14 28 764 806
_______ _______ _______ _______
At 31 March 2024 323 318 14,008 14,649
_______ _______ _______ _______
Carrying amount
At 31 March 2024 41 83 2,292 2,416
_______ _______ _______ _______
At 31 March 2023 55 111 3,056 3,222
_______ _______ _______ _______
6. Investments
Other investments other than loans Total
£ £
Cost
At 1 April 2023 7,953 7,953
Additions 71,202 71,202
Disposals ( 74,866) ( 74,866)
_______ _______
At 31 March 2024 4,289 4,289
_______ _______
Impairment
At 1 April 2023 and 31 March 2024 - -
_______ _______
Carrying amount
At 31 March 2024 4,289 4,289
_______ _______
At 31 March 2023 7,953 7,953
_______ _______
7. Debtors
2024 2023
£ £
Other debtors 18,242 19,970
_______ _______
8. Creditors: amounts falling due within one year
2024 2023
£ £
Corporation tax 18,485 21,292
Other creditors 5,000 5,380
_______ _______
23,485 26,672
_______ _______
9. Operating leases
The company as lessee
The total future minimum lease payments under non-cancellable operating leases are as follows:
£ £
Not later than 1 year 867 3,466
Later than 1 year and not later than 5 years - 867
_______ _______
867 4,333
_______ _______
10. Directors advances, credits and guarantees
During the year the directors entered into the following advances and credits with the company:
2024
Balance brought forward Advances /(credits) to the directors Amounts repaid Balance o/standing
£ £ £ £
Dr Natalia Ferri 7,724 35,266 ( 34,974) 8,016
Dr Steven Hamilton 7,724 35,266 ( 34,974) 8,016
_______ _______ _______ _______
15,448 70,532 ( 69,948) 16,032
_______ _______ _______ _______
2023
Balance brought forward Advances /(credits) to the directors Amounts repaid Balance o/standing
£ £ £ £
Dr Natalia Ferri 7,065 31,434 ( 30,775) 7,724
Dr Steven Hamilton 7,065 31,434 ( 30,775) 7,724
_______ _______ _______ _______
14,130 62,868 ( 61,550) 15,448
_______ _______ _______ _______
Director's loan accounts are repayable on demand, interest has been charged at HMRC's official rate.